# Steady-State Study of Extended Phenytoin Sodium Capsules 100 mg and Dilantin® Kapseals® 100 mg

> **NCT00647621** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 72 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Extended Phenytoin Sodium Capsules 100 mg
- **DRUG:** Dilantin® Kapseals® 100 mg

## Key facts

- **NCT ID:** NCT00647621
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00647621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00647621, "Steady-State Study of Extended Phenytoin Sodium Capsules 100 mg and Dilantin® Kapseals® 100 mg". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00647621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*